Innovation Pharmaceuticals Inc (IPIX)

[frrol]

GSK apparently stopped development of the psoriasis drug at this phase 2A and it's easy to see why: the drug did not show significant clinical benefit, in magnitude or statistical reliability. And the only dose dependency demonstrated was in systemic exposure and against placebo, not among dosing cohorts. Ie, the drug plateaued at the lower dose (and maybe even lower). In fact for PASI-75 at day 84, correlation was negative: the higher doses did worse against placebo. This is why it is foolish to assume more drug = more effect, the claim of some P pumping here. You don't know until you test. These are pharmaceutical drugs, not magic beans.

The hope for our P phase 2B is that we haven't reached that plateau and that the results are strong and statistically reliable.